ERNEXA THERAPEUTICS INC

ERNANASDAQ

🏆 #3785 by market capEarnings Nov 6US Equity

$4.39▼ $0.14 (−3.09%)

Live

1h—

24h▼ 3.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$5M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

83.5%

High

💵FCF Margin

283.5%

Strong

⚖️P/S Ratio

12.5x

Elevated

Otter Score

Fair

No chart data available for ERNA.

Trading Snapshot

Day Range: $4.32 – $4.41
52-Week Range: $3.18 – $71.50
Volume: $4.89B
Avg Volume: $4.08B
Shares Outstanding: 1.2M
Next Earnings: Sep 14, 2026

Fundamentals Snapshot

Annual Revenue: $591,136
Last Q Revenue: $158,252
P/E Ratio: —
P/S Ratio: 12.5x
EPS (TTM): $-25.77
Dividend Yield: 0.27%

Why Investors Own ERNA

✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
✓Healthy economics — 60% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$591,136▲ +16.9% YoY

Gross Margin (TTM)

59.6%▲ +2.9% YoY

Operating Income (TTM)

$210,445▲ +16.9% YoY

Free Cash Flow (TTM)

$102,858▲ +16.9% YoY

About ERNEXA THERAPEUTICS INC

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.

🦦